| Date Filed | Type | Description |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/16/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2021 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 01/29/2021 |
SC 13G
| JNE Partners LLP reports a 0% stake in Prevail Therapeutics Inc. |
| 01/27/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 01/22/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/22/2021 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 01/22/2021 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 01/22/2021 |
8-K
| Resignation/termination of a director |
| 01/22/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/22/2021 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 01/22/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/20/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/20/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/14/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 01/14/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/12/2021 |
GN
| INVESTIGATION ALERT: Halper Sadeh LLP Investigates BPFH, MDCA, MTSC, PRVL; Shareholders Are Encouraged to Contact the Firm |
| 01/07/2021 |
GN
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XLNX, ANH, TCF, PRVL; Shareholders Are Encouraged to Contact the Firm |
| 01/05/2021 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 01/05/2021 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 12/22/2020 |
SC 13D
| ELI LILLY & Co reports a 53.3% stake in Prevail Therapeutics Inc. |
| 12/22/2020 |
SC 14D9
| Form SC 14D9 - Solicitation, recommendation statements: |
| 12/22/2020 |
SC TO-T
| Form SC TO-T - Tender offer statement by Third Party: |
| 12/19/2020 |
GN
| SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies – ANH, TCF, PRVL, ZAGG |
| 12/16/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout |
| 12/16/2020 |
GN
| PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm |
| 12/15/2020 |
SC14D9C
| Form SC14D9C - Written communication relating to third party tender offer: |
| 12/15/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"FORM 8-K",
"Agreement and Plan of Merger, by and among Prevail Therapeutics Inc., Eli Lilly and Company and Tyto Acquisition Corporation (pursuant to Item 601(b)(2) of Regulation S-K, the Company hereby agrees to supplementally furnish to the SEC upon request any omitted schedule or exhibit to the Agreement and Plan of Merger)",
"Tender and Support Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation, OrbiMed Private Investments VI, LP",
"Tender and Support Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation, Pontifax (Cayman) V L.P., Pontifax (China) V L.P., Pontifax (Israel) V L.P. and Pontifax Late Stage Fund L.P",
"Tender and Support Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation and Asa Abeliovich, M.D., Ph.D",
"Form of Contingent Value Right Agreement, by and among Eli Lilly and Company, Tyto Acquisition Corporation and a rights agent mutually agreeable to Eli Lilly and Company and Prevail Therapeutics Inc",
"Lilly Announces Agreement to Acquire Prevail Therapeutics" |
|
| 12/15/2020 |
SC TO-C
| Form SC TO-C - Written communication relating to an issuer or third party: |
| 12/11/2020 |
GN
| Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations |
| 11/18/2020 |
GN
| Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001 |
| 11/13/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
|